{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:43:23Z","timestamp":1770983003052,"version":"3.50.1"},"reference-count":7,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[1998,1,1]],"date-time":"1998-01-01T00:00:00Z","timestamp":883612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[1998,1,1]],"date-time":"1998-01-01T00:00:00Z","timestamp":883612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis"],"published-print":{"date-parts":[[1998]]},"abstract":"<jats:p>Objective: This study evaluated changes in health-related quality of life (HRQL) outcomes of once-daily omeprazole compared with ranitidine for the short-term treatment of patients with poorly responsive symptomatic gastroesophageal reflux disease (GERD). Methods: A double-blind, randomized clinical trial, compared omeprazole versus ranitidine for the treatment of poorly responsive GERD. Eligible patients had a history of predominant heartburn symptoms with symptomatic heartburn after 6 weeks of ranitidine treatment. Patients were randomized to omeprazole 20 mg once daily (n = 156) or ranitidine 150 mg twice daily (n = 161) and followed for 8 weeks. Assessments were completed at baseline and after 8 weeks with physician-rated symptoms: Gastrointestinal Symptom Rating Scale (GSRS); Psychological General Well-Being (PGWB) Index; Sleep Scale; Impact on Daily Activities Scale, and Overall Treatment Effect. Primary HRQL endpoints were the GSRS reflux scale and PGWB total score. Results: No differences between the 2 treatment groups were observed in baseline demographic, clinical or HRQL measures. After 8 weeks, omeprazole-treated patients had greater improvement in GSRS reflux scale scores (p&lt;0.0001) and PGWB total scores (p = 0.019) compared with ranitidine-treated patients. Significant between group differences favoring omeprazole were also observed in GSRS total scores (p&lt;0.0001), abdominal pain scale scores (p = 0.003), and indigestion scale scores (p = 0.003), Impact on Daily Activities (p = 0.001), PGWB positive well-being (p = 0.015), anxiety (p = 0.030), and general health scale scores (p = 0.010). Patient ratings of overall treatment effect demonstrated the significantly (p&lt;0.0001) greater benefits of omeprazole (mean = 5.26) compared with ranitidine treatment (mean = 3.83). Conclusions: Omeprazole treatment significantly reduced persistent reflux-related symptoms and normalized psychological well-being compared with ranitidine in poorly responsive symptomatic patients with GERD.<\/jats:p>","DOI":"10.1159\/000016878","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T17:25:18Z","timestamp":1050427518000},"page":"284-291","source":"Crossref","is-referenced-by-count":45,"title":["Health-Related Quality of Life Outcomes of Omeprazole versus Ranitidine in Poorly Responsive Symptomatic Gastroesophageal Reflux Disease"],"prefix":"10.1159","volume":"16","author":[{"given":"Dennis","family":"Revicki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Maton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[1999,1,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.152.4.717"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.156.5.477"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/00365529850170766"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510263331703"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00354-9"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304013281302"}],"container-title":["Digestive Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/16878","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/16878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:47:56Z","timestamp":1745470076000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000016878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998]]},"references-count":7,"journal-issue":{"issue":"5","published-online":{"date-parts":[[1999,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000016878","archive":["Portico"],"relation":{},"ISSN":["0257-2753","1421-9875"],"issn-type":[{"value":"0257-2753","type":"print"},{"value":"1421-9875","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998]]}}}